Artax Biopharma is pioneering a novel approach to treating autoimmune diseases through the development of first-in-class Nck modulators. These small molecules are designed to inhibit the binding of Nck to the T cell receptor (TCR), which plays a crucial role in T cell activation. By preventing Nck recruitment upon TCR activation, Artax's technology aims to modulate the immune response without causing immunosuppression. This innovative strategy allows the immune system to maintain its ability to combat foreign pathogens while rebalancing the response to self-antigens, thereby addressing the underlying causes of T cell-mediated diseases such as psoriasis and atopic dermatitis.

The lead candidate, AX-158, is currently undergoing clinical evaluation, with promising results anticipated from ongoing Phase 2 trials. Artax Biopharma's approach not only targets specific autoimmune conditions but also holds the potential for broader applications across various T cell-mediated diseases. The company is committed to advancing its proprietary pipeline, with additional candidates like AX-194 in preclinical development, further solidifying its position in the field of immunomodulation. Through this focused research and development strategy, Artax Biopharma aims to provide effective treatments that enhance patient quality of life while preserving immune function.

United States

Artax Biopharma is a development-stage biopharmaceutical company dedicated to the development of new therapies for autoimmune and inflammatory diseases. Artax Biopharma is developing the next generation of drugs targeting the interaction between TCR and Nck, which is responsible for T-cell activation. Specific control over T-cells through TCR, provides the compounds with the potential to become first-in-class immunomodulators for the treatment of a wide range of autoimmune and inflammatory diseases.

Artax Biopharma

Company Details